Conference Programme
Maximising Returns from Life Science Innovation
3 December 2025
Maximising Returns from Life Science Innovation
Programme
The 2025 Keynote Programme at Genesis will explore the exciting potential offered by innovation in life sciences to address global unmet medical needs, investment returns and new treatment development challenges. The sessions will discuss how the barriers to progress can be defeated through creative thinking in R&D, collaboration, investment and patient access to translate the golden triangle of ‘technology-people-money’ into value creation for all stakeholders.
Draft Keynote Programme
Registration
Welcome from One Nucleus
Tony Jones, CEO, One Nucleus
SESSION 1
Keynote Address: Winners & Losers 2025
Mike Ward, Global Head of Life Sciences Thought Leadership, Clarivate
Changeover Video
Keynote Panel: The Changing Life Science Investment Landscape
- With larger deal sizes, is the gap between the haves and have nots widening?
- Innovative business models vs investor appetite
- Does founder diversity bring investment opportunity diversity?
- Are capital pools on the move?
– Moderator – TBC
– Panellists: Rowan Gardner, PrecisionLife, Janette Thomas, Five Alarm Bio, TBC, Eli Lilly, Soyoung Park, 1004 Venture Partners
Coffee Break
SESSION 2
Keynote Panel: How Will New Medicines Be Developed and Paid For in 2050?
- Technologies changing R&D approaches
- Clinical trial designs and regulatory evolution
- Reimbursement models
- Delivering global healthcare equity
– Moderator – TBC
– Panellists: Melanie Leveridge, AstraZeneca, Lisa Urquhart, Pierre Arsene, Mursla Bio, Speaker tbc, trialmed
Changeover Video
Keynote Panel: Being Patient-Centric: Lessons from Rare Diseases R&D
- Patient engagement and access
- Utilising Real-World-Evidence and Experience in R&D
- Clinical trial design
- Innovative partnerships
– Moderator – TBC
– Panellists: Femida Gwadry-Sridhar, Pulse Infoframe, Roni Jortner, Aspire Biosciences, Speaker TBC, Thermo Fisher
Lunch Break
SESSION 3
Keynote Panel: Technologies for Impact?
- Which technologies are exciting the life science R&D community?
- Is all innovation now inter-disciplinary?
- How are the biggest fears of innovation being addressed?
- What constitutes validation for investors and R&D partners?
– Moderator – Simon Bradbury, Withers & Rogers
– Panellists: Renos Savva, Discovery Park, Catherine Stace, Kuano, Olga Wlodek, Constructive Bio, Kerstin Papenfuss, Deep Science Ventures
Changeover Video
Keynote Panel: How to Separate on Good Terms If Things Don’t Work
Many business relationships do not work out for whether due to problems with the technology, personnel, available resource or changes in strategy. Is there a common approach to deal with such challenges when:
- Encountering a roadblock
- Communication – internal and external
- Being prepared from the outset
- After the separation
– Moderator – TBC
– Panellists: Ricky Martin, Hyper Recruitment Solutions, Caroline Austin, AstraZeneca, Anji Miller, LifeArc
Changeover Video
Fireside Chat: What Comprises an Innovation-friendly Environment?
- Speakers TBC
Fireside Chat: A Global Approach to Early Stage Fundraising
- Nick Sireau, Serenatis Bio and Dennis Ford, Life Science Nation
Coffee Break
SESSION 4
Fireside Chat: What Has Surprised Us Most in the Past 25 Years?
- Professor Ian Charles OBE & Sue Charles in conversation
Fireside Chat: A Patient’s Perspective
- Eddie Blair, Board Trustee, Quadram Institute and Vice-Chair, East Genomic Medicine Service Alliance Patient and Public Voice Panel
- Chris Hind, East Genomic Medicine Service Alliance Patient and Public Voice Panel and Public Governor, Norfolk and Norwich University Hospital
Keynote Panel: Has the Past 25 Years of Life Sciences R&D Delivered on Expectations?
- What was the ambition in year 2000?
- Was it achieved?
- If not, why not?
- What provides optimism by 2050?
– Moderator: Mike Ward, Clarivate
– Priya Mande, RNAvate
– Anne Lane, UCL Business
– Madeleine Wakeling, Harness Therapeutics
– Hayley French, Domainex
Closing Remarks
Drinks Reception
Close
Programme is subject to change